Pfizer Inc., AstraZeneca Plc and other companies have struck deals with the Trump administration in recent months ...

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain ...

Merck's oral PCSK inhibitor for cholesterol, enlicitide, and its cancer antibody-drug conjugate sacituzumab tirumotecan ...

A multicentre clinical trial led by a researcher from the University of Sherbrooke will test a new therapeutic approach to moderate asthma. The study will include 150 patients, including 50 in Quebec, ...

Preview this article 1 min Regeneron's $2 billion plan for its Saratoga County facility got a big boost recently. © 2025 ...

In this video, Carolyn K. Pan, MD, a clinical professor of ophthalmology at Stanford University, discussed highlights in wet ...

Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.

Tech CEO compensation hit record levels in 2025 as industry titans were rewarded for leading innovation and growth. Elon Musk ...

GSK's asthma drug Exdensur, the first biologic for twice-yearly dosing, gains FDA approval for severe asthma treatment.

WATCH: Behind the scenes of big ticket litigation — lessons from the courts ...

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.

In this video, Jonathan A. Bernstein, MD, discusses an American College of Allergy, Asthma & Immunology Annual Scientific ...